• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Time for a regulatory framework for pediatric medications in Canada.

作者信息

Gilpin Andrea, Bérubé Sophie, Moore-Hepburn Charlotte, Lacaze-Masmonteil Thierry, Samiee-Zafarghandy Samira, Rieder Michael, Gruenwoldt Emily, MacLeod Stuart, Litalien Catherine

机构信息

The Rosalind & Morris Goodman Family Pediatric Formulations Centre of the Centre Hospitalier Universitaire (CHU) Ste-Justine (Gilpin [at the time of article submission], Bérubé, Litalien), Montréal, Que.; Health Canada (Gilpin), Ottawa, Ont.; Department of Pediatrics (Moore-Hepburn), University of Toronto, Toronto, Ont.; Section of Neonatology (Lacaze-Masmonteil), Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alta.; Division of Neonatology (Samiee-Zafarghandy), Department of Pediatrics, McMaster Children's Hospital, McMaster University, Hamilton, Ont.; Division of Pediatric Clinical Pharmacology (Rieder), Department of Pediatrics, University of Western Ontario, London, Ont.; Children's Healthcare Canada (Gruenwoldt), Ottawa, Ont.; Department of Pediatrics (MacLeod), Faculty of Medicine, University of British Columbia, Vancouver, BC; Department of Pediatrics (Litalien), University of Montreal, Montréal, Que.

出版信息

CMAJ. 2022 May 16;194(19):E678-E680. doi: 10.1503/cmaj.220044.

DOI:10.1503/cmaj.220044
PMID:35577378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9438731/
Abstract
摘要

相似文献

1
Time for a regulatory framework for pediatric medications in Canada.加拿大需要建立儿科药物监管框架的时候了。
CMAJ. 2022 May 16;194(19):E678-E680. doi: 10.1503/cmaj.220044.
2
The timeliness of new drug approvals in Canada.加拿大新药审批的及时性。
Int J Health Serv. 1995;25(1):153-65; discussion 167-71. doi: 10.2190/3XHM-EW8F-5HJY-2D5N.
3
Pediatric drug data in Canadian drug monographs: a descriptive analysis.加拿大药品说明书中的儿科用药数据：描述性分析
CMAJ Open. 2020 Aug 31;8(3):E522-E529. doi: 10.9778/cmajo.20200010. Print 2020 Jul-Sep.
4
Pediatric drug regulation: International perspectives.儿科药物监管：国际视角
Paediatr Anaesth. 2019 Jun;29(6):572-582. doi: 10.1111/pan.13638. Epub 2019 Apr 14.
5
A comparison of regulatory approval times for new chemical entities in Australia, Canada, Sweden, the United Kingdom, and the United States.澳大利亚、加拿大、瑞典、英国和美国新化学实体的监管批准时间比较。
J Clin Pharmacol. 1992 Oct;32(10):889-96. doi: 10.1002/j.1552-4604.1992.tb04634.x.
6
Current practices and reform proposals for the regulation of advanced medicinal products in Canada.加拿大先进药品监管的现行做法与改革建议
Regen Med. 2015;10(5):647-63. doi: 10.2217/rme.15.28.
7
Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand.加拿大和新西兰新药监管批准数量及时间的比较。
Regul Toxicol Pharmacol. 2019 Feb;101:24-28. doi: 10.1016/j.yrtph.2018.10.019. Epub 2018 Nov 1.
8
Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.1996年至1998年期间，加拿大、澳大利亚、瑞典、英国和美国批准新药所需的时间。
CMAJ. 2000 Feb 22;162(4):501-4.
9
"New approach" as Health Canada seeks conditional licences for drugs, new pediatric office.随着加拿大卫生部寻求药品的有条件许可，新的儿科诊所采用“新方法”。
CMAJ. 2005 Mar 29;172(7):864. doi: 10.1503/cmaj.050244. Epub 2005 Mar 2.
10
Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.加拿大和新西兰针对罕见病的新药的监管批准及纳入公共药品计划清单。
J Popul Ther Clin Pharmacol. 2020 Jun 1;27(2):e58-e67. doi: 10.15586/jptcp.v27i2.673.

引用本文的文献

1
Reforming Paediatric Drug Regulations in Canada: A Clinical and an Access Imperative.改革加拿大儿科药物监管规定：临床和准入的迫切需要。
Healthc Policy. 2023 Aug;19(1):54-64. doi: 10.12927/hcpol.2023.27157.
2
The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-Children and Adolescents with IBD.2023年炎症性肠病在加拿大的影响：特殊人群——炎症性肠病患儿和青少年
J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S35-S44. doi: 10.1093/jcag/gwad016. eCollection 2023 Sep.
3
Urgent call for guidance supporting gene-based drug dosing in children and adolescents.紧急呼吁为儿童和青少年基于基因的药物剂量制定提供指导支持。
Paediatr Child Health. 2023 Jun 6;28(4):205-245. doi: 10.1093/pch/pxad003. eCollection 2023 Jul.
4
Drug Prescriptions Requiring Compounding at a Canadian University Affiliated Pediatric Hospital: A Cross-Sectional Study.加拿大一所大学附属医院需要配制的药物处方：一项横断面研究。
Children (Basel). 2023 Jan 11;10(1):147. doi: 10.3390/children10010147.

本文引用的文献

1
Pharmaceutical Compounding: a History, Regulatory Overview, and Systematic Review of Compounding Errors.药物配制：历史、监管概述及配制错误的系统评价。
J Med Toxicol. 2021 Apr;17(2):197-217. doi: 10.1007/s13181-020-00814-3. Epub 2020 Nov 2.
2
Providing Suitable Pediatric Formulations for Canadian Children: A Call for Action.为加拿大儿童提供合适的儿科制剂：行动呼吁。
Can J Hosp Pharm. 2020 Fall;73(4):247-256. Epub 2020 Oct 1.
3
Pediatric drug data in Canadian drug monographs: a descriptive analysis.加拿大药品说明书中的儿科用药数据：描述性分析
CMAJ Open. 2020 Aug 31;8(3):E522-E529. doi: 10.9778/cmajo.20200010. Print 2020 Jul-Sep.
4
Patient safety issues associated with the use of compounded medicines as alternatives to approved pharmaceutical products in Europe and how best practice can improve outcomes.欧洲与使用复方药物作为已批准药品替代品相关的患者安全问题，以及如何通过最佳实践改善结果。
Int J Risk Saf Med. 2020;31(3):133-144. doi: 10.3233/JRS-200002.
5
Global Pediatric Drug Development.全球儿科药物研发
Curr Ther Res Clin Exp. 2019 Feb 13;90:135-142. doi: 10.1016/j.curtheres.2019.02.001. eCollection 2019.
6
Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development.监管激励计划对儿科药物研发未来的影响。
Ther Innov Regul Sci. 2019 Sep;53(5):609-614. doi: 10.1177/2168479019837522. Epub 2019 Apr 14.
7
Off-label Medication Prescribing Patterns in Pediatrics: An Update.儿科非适应证用药处方模式：最新进展
Hosp Pediatr. 2019 Mar;9(3):186-193. doi: 10.1542/hpeds.2018-0168. Epub 2019 Feb 11.